Display options
Cite
Possamaï D, Hanafi LA, Bellemare-Pelletier A, et al. MHC class I antigen cross-presentation mediated by PapMV nanoparticles in human antigen-presenting cells is dependent on autophagy. PLoS One. 2021;16(12):e0261987doi: 10.1371/journal.pone.0261987.
Possamaï, D., Hanafi, L. A., Bellemare-Pelletier, A., Hamelin, K., Thébault, P., Hébert, M. J., Gagnon, �. �., Leclerc, D., & Lapointe, R. (2021). MHC class I antigen cross-presentation mediated by PapMV nanoparticles in human antigen-presenting cells is dependent on autophagy. PloS one, 16(12), e0261987. https://doi.org/10.1371/journal.pone.0261987
Possamaï, David, et al. "MHC class I antigen cross-presentation mediated by PapMV nanoparticles in human antigen-presenting cells is dependent on autophagy." PloS one vol. 16,12 (2021): e0261987. doi: https://doi.org/10.1371/journal.pone.0261987
Possamaï D, Hanafi LA, Bellemare-Pelletier A, Hamelin K, Thébault P, Hébert MJ, Gagnon É, Leclerc D, Lapointe R. MHC class I antigen cross-presentation mediated by PapMV nanoparticles in human antigen-presenting cells is dependent on autophagy. PLoS One. 2021 Dec 31;16(12):e0261987. doi: 10.1371/journal.pone.0261987. eCollection 2021. PMID: 34972158; PMCID: PMC8719699.
Copy Download .nbib Format: NLM
Share it on

PLoS One. 2021 Dec 31;16(12):e0261987. doi: 10.1371/journal.pone.0261987. eCollection 2021.

MHC class I antigen cross-presentation mediated by PapMV nanoparticles in human antigen-presenting cells is dependent on autophagy.

PloS one

David Possamaï, Laïla-Aïcha Hanafi, Angélique Bellemare-Pelletier, Katia Hamelin, Paméla Thébault, Marie-Josée Hébert, Étienne Gagnon, Denis Leclerc, Réjean Lapointe

Affiliations

  1. Centre de recherche du Centre hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
  2. Institut de Recherche en Immunologie et Cancérologie, Montréal, Québec, Canada.
  3. Département de Microbiologie et Immunologie, Université de Montréal, Montréal, Québec, Canada.
  4. Centre de recherche en infectiologie, Centre hospitalier universitaire de Québec, Québec, Québec, Canada.
  5. Département de Microbiologie, Infectiologie et Immunologie, Université Laval, Québec, Québec, Canada.
  6. Département de Médecine, Faculté de Médecine, Université de Montréal, Montréal, Québec, Canada.

PMID: 34972158 PMCID: PMC8719699 DOI: 10.1371/journal.pone.0261987

Abstract

Nanoparticles made of the coat protein of papaya mosaic virus (PapMV) and a single-strand RNA were previously shown to be an efficient antigen presentation system for the trigger of cellular immunity. Engineering of PapMV nano with a cytotoxic T lymphocyte epitope was previously shown activating specific T lymphocytes through a proteasome-independent major histocompatibility complex class I (MHC-I) cross-presentation. In this study, we provide new insights into the mechanism of the MHC-I cross-presentation mediated by PapMV nanoparticles. We demonstrate that PapMV nanoparticles do not require the transporter associated with antigen presentation (TAP), but rather depend on lysosome acidification and cathepsin S protease activity for presentation of the T cell epitope. We have also linked the induction of autophagy with this vacuolar MHC-I cross-presentation process. Interestingly, autophagy is induced in antigen-presenting cells after PapMV nanoparticles exposure and inhibition of autophagy reduce MHC-I cross-presentation. This study demonstrates that autophagy is associated with TAP- and proteasome-independent MHC-I cross-presentation. A deeper understanding of the autophagy-dependent MHC-I cross-presentation will be useful in designing vaccination platforms that aim to trigger an efficient cytotoxic T lymphocyte response.

Conflict of interest statement

I have read the journal’s policy and the authors of this manuscript have the following competing interests: D.L. is the founder and a shareholder of Folia Biotech. Inc., a Canadian Biotechnology Compa

References

  1. Immunity. 2004 Aug;21(2):155-65 - PubMed
  2. Mol Immunol. 2013 Sep;55(2):146-8 - PubMed
  3. Autophagy. 2006 Apr-Jun;2(2):122-5 - PubMed
  4. Mol Immunol. 2013 Sep;55(2):139-42 - PubMed
  5. Semin Cell Dev Biol. 2020 May;101:68-76 - PubMed
  6. Semin Immunol. 2017 Dec;34:123-132 - PubMed
  7. Annu Rev Immunol. 2018 Apr 26;36:717-753 - PubMed
  8. Proteomics. 2013 Apr;13(7):1108-20 - PubMed
  9. Vaccines (Basel). 2015 Aug 05;3(3):620-37 - PubMed
  10. Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10326-31 - PubMed
  11. Nat Immunol. 2009 May;10(5):480-7 - PubMed
  12. J Exp Med. 2013 Feb 11;210(2):287-300 - PubMed
  13. Eur J Immunol. 2017 Oct;47(10):1819-1834 - PubMed
  14. Immunol Cell Biol. 2011 Aug;89(6):681-8 - PubMed
  15. Science. 2010 Apr 2;328(5974):102-6 - PubMed
  16. Cell Host Microbe. 2013 Jul 17;14(1):15-25 - PubMed
  17. Immunol Cell Biol. 2016 Nov;94(10):964-974 - PubMed
  18. Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4788-93 - PubMed
  19. Mol Immunol. 2013 Sep;55(2):113-6 - PubMed
  20. NPJ Vaccines. 2019 May 15;4:17 - PubMed
  21. Blood. 2012 Aug 2;120(5):994-1004 - PubMed
  22. J Immunol. 2010 Jan 1;184(1):9-15 - PubMed
  23. Cell Death Dis. 2018 May 22;9(6):605 - PubMed
  24. Nat Rev Mol Cell Biol. 2018 Jun;19(6):349-364 - PubMed
  25. Vaccine. 2013 Apr 26;31(18):2310-6 - PubMed
  26. PLoS Pathog. 2009 Jun;5(6):e1000490 - PubMed
  27. J Immunol. 1997 May 15;158(10):4555-63 - PubMed
  28. Front Immunol. 2021 Feb 25;12:628429 - PubMed
  29. Nat Immunol. 2008 May;9(5):551-7 - PubMed
  30. Mol Immunol. 2019 Sep;113:2-5 - PubMed
  31. Immunology. 2014 Jan;141(1):1-8 - PubMed
  32. J Immunother Cancer. 2019 Apr 26;7(1):114 - PubMed
  33. Immunogenetics. 1985;21(3):235-46 - PubMed
  34. Immunol Rev. 1988 Dec;106:129-47 - PubMed
  35. Nat Rev Immunol. 2013 Oct;13(10):722-37 - PubMed
  36. Eur J Immunol. 2004 Apr;34(4):952-60 - PubMed
  37. Nanomedicine. 2018 Oct;14(7):2317-2327 - PubMed
  38. Vaccine. 2010 Aug 2;28(34):5617-26 - PubMed
  39. PLoS One. 2008 Sep 19;3(9):e3247 - PubMed
  40. J Immunol. 2013 Mar 15;190(6):2791-806 - PubMed
  41. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Jan;12(1):e1579 - PubMed
  42. J Virol. 2007 Feb;81(3):1319-26 - PubMed
  43. Autophagy. 2009 Oct;5(7):1026-9 - PubMed
  44. Virology. 2009 Dec 5;395(1):45-55 - PubMed
  45. J Cell Biol. 2012 May 28;197(5):659-75 - PubMed
  46. PLoS One. 2014 Feb 27;9(2):e89897 - PubMed
  47. Autophagy. 2013 Jun 1;9(6):931-2 - PubMed
  48. Front Immunol. 2015 Jun 05;6:298 - PubMed
  49. Cell Rep. 2016 May 3;15(5):1076-1087 - PubMed
  50. Cancer Res. 2003 Jun 1;63(11):2836-43 - PubMed
  51. Nat Rev Immunol. 2010 Nov;10(11):787-96 - PubMed
  52. Intervirology. 2013;56(3):141-65 - PubMed
  53. Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15801-6 - PubMed
  54. Mol Immunol. 2002 Oct;39(3-4):181-202 - PubMed

Publication Types

Grant support